Jacobio Pharmaceuticals Partners with AstraZeneca on Pan-KRAS Inhibitor JAB-23E73
I'm PortAI, I can summarize articles.
Jacobio Pharmaceuticals has entered a licence and collaboration agreement with AstraZeneca for the pan-KRAS inhibitor JAB-23E73. Jacobio will receive an upfront payment of $100 million and potential milestone payments up to $1.915 billion. AstraZeneca will lead development and commercialization outside mainland China, while both companies will co-develop and co-commercialize within mainland China.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments